160 related articles for article (PubMed ID: 38849944)
1. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
[TBL] [Abstract][Full Text] [Related]
2. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
Wessels AM; Dowsett SA; Sims JR
J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
4. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
[TBL] [Abstract][Full Text] [Related]
5. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial.
Lam LC; Chan WC; Leung T; Fung AW; Leung EM
PLoS One; 2015; 10(3):e0118173. PubMed ID: 25826620
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
8. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS
J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605
[TBL] [Abstract][Full Text] [Related]
9. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
[TBL] [Abstract][Full Text] [Related]
10. Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
Dyer AH; Murphy C; Segurado R; Lawlor B; Kennelly SP;
J Gerontol A Biol Sci Med Sci; 2020 Apr; 75(5):987-994. PubMed ID: 31613323
[TBL] [Abstract][Full Text] [Related]
11. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
12. Randomized, sham-controlled, clinical trial of repetitive transcranial magnetic stimulation for patients with Alzheimer's dementia in Japan.
Saitoh Y; Hosomi K; Mano T; Takeya Y; Tagami S; Mori N; Matsugi A; Jono Y; Harada H; Yamada T; Miyake A
Front Aging Neurosci; 2022; 14():993306. PubMed ID: 36313021
[TBL] [Abstract][Full Text] [Related]
13. Minimal clinically important difference in Alzheimer's disease: Rapid review.
Muir RT; Hill MD; Black SE; Smith EE
Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
[TBL] [Abstract][Full Text] [Related]
14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
15. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
[TBL] [Abstract][Full Text] [Related]
16. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
Nogueira J; Freitas S; Duro D; Almeida J; Santana I
Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
18. Body, Brain, Life for Cognitive Decline (BBL-CD): protocol for a multidomain dementia risk reduction randomized controlled trial for subjective cognitive decline and mild cognitive impairment.
McMaster M; Kim S; Clare L; Torres SJ; D'Este C; Anstey KJ
Clin Interv Aging; 2018; 13():2397-2406. PubMed ID: 30538436
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
